China’s Brii says its COVID-19 antibody cocktail retains activity against Omicron

China’s Brii Biosciences stated on Sunday lab research confirmed that its COVID-19 antibody cocktail retained exercise in opposition to the Omicron variant, though one of many antibodies confirmed a considerable drop in exercise when examined alone.

Take a look at particulars for the dual-antibody remedy, which final week turned the primary accredited COVID-19 antibody cocktail in China, wouldn’t be out there till publication in a scientific journal, however outcomes from three impartial labs confirmed comparable sample, Brii chief govt Hong Zhi stated on Monday.

Though no buy order for the remedy has been introduced, the agency was in a position to safe manufacturing capability of 1 million doses for 2022 and 2023 every, Hong stated in an investor name, including it already has about 80,000 doses out there in its stock.

Hong stated the agency hoped to obtain stockpiling orders for the antibody mixture. “These are crucial for us as a small firm to essentially handle our money move on the identical time addressing a public pandemic.”

The agency, but to reveal any in-house manufacturing capability for the drug, is partnering with WuXi Biologics for manufacturing.